Literature DB >> 18413773

The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini.

C Elizabeth Caldon1, Alexander Swarbrick, Christine S L Lee, Robert L Sutherland, Elizabeth A Musgrove.   

Abstract

Overexpression of the helix-loop-helix (HLH) protein Id1 has been associated with metastasis in breast cancer, but its role in models of early breast tumorigenesis is not well characterized. We show that the down-regulation of endogenous Id1 via proteosomal degradation and relocalization from the nucleus to the cytoplasm is an early event in the formation of mammary epithelial acini. Overexpression of Id1 in both human MCF-10A and primary mouse mammary epithelial cells disrupted normal acinar development by increasing acinar volume. This occurred in an HLH domain-dependent fashion via an increase in S phase. Id1 overexpression also increased apoptosis leading to accelerated luminal clearance, and this was reversed by coexpression of the proto-oncogene Bcl2, leading to large, disorganized structures with filled lumina. Id1 overexpression was unable to increase the volume of cyclin D1(-/-) acini, indicating that Id1 is dependent on cyclin D1 for its proliferative effects. In summary, Id1 may contribute to early breast cancer by promoting excessive proliferation through cyclin D1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413773     DOI: 10.1158/0008-5472.CAN-07-3079

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features.

Authors:  Sophie Lehn; Nicholas P Tobin; Pontus Berglund; Kristina Nilsson; Andrew H Sims; Karin Jirström; Pirkko Härkönen; Rebecca Lamb; Göran Landberg
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

2.  Protein kinase Cα signaling regulates inhibitor of DNA binding 1 in the intestinal epithelium.

Authors:  Fang Hao; Marybeth A Pysz; Kathryn J Curry; Kristin N Haas; Steven J Seedhouse; Adrian R Black; Jennifer D Black
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

3.  ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.

Authors:  Hao Geng; Brooks L Rademacher; Janet Pittsenbarger; Chung-Ying Huang; Christopher T Harvey; Marie C Lafortune; Anne Myrthue; Mark Garzotto; Peter S Nelson; Tomasz M Beer; David Z Qian
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

4.  Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Andrew Burgess; Andrew J Deans; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

5.  Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

6.  Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development.

Authors:  Radhika Nair; Simon Junankar; Sandra O'Toole; Jaynish Shah; Alexander D Borowsky; J Michael Bishop; Alexander Swarbrick
Journal:  PLoS One       Date:  2010-08-03       Impact factor: 3.240

7.  Cyclin D1, Id1 and EMT in breast cancer.

Authors:  Nicholas P Tobin; Andrew H Sims; Katja L Lundgren; Sophie Lehn; Göran Landberg
Journal:  BMC Cancer       Date:  2011-09-28       Impact factor: 4.430

8.  Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells.

Authors:  Samuel Rogers; Brian S Gloss; Christine S Lee; Claudio Marcelo Sergio; Marcel E Dinger; Elizabeth A Musgrove; Andrew Burgess; Catherine Elizabeth Caldon
Journal:  Cell Div       Date:  2015-02-19       Impact factor: 5.130

9.  BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast.

Authors:  E K A Millar; L R Anderson; C M McNeil; S A O'Toole; M Pinese; P Crea; A L Morey; A V Biankin; S M Henshall; E A Musgrove; R L Sutherland; A J Butt
Journal:  Br J Cancer       Date:  2008-12-09       Impact factor: 7.640

10.  GCIP functions as a tumor suppressor in non-small cell lung cancer by suppressing Id1-mediated tumor promotion.

Authors:  Kuan-yu Chen; Chao-chung Chen; Yau-lin Tseng; Yi-chien Chang; Ming-chung Chang
Journal:  Oncotarget       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.